AR031335A1 - Nuevos usos de combinaciones de agonistas de 5-ht1a e inhibidores de la recaptacion de serotonina - Google Patents

Nuevos usos de combinaciones de agonistas de 5-ht1a e inhibidores de la recaptacion de serotonina

Info

Publication number
AR031335A1
AR031335A1 ARP010105299A ARP010105299A AR031335A1 AR 031335 A1 AR031335 A1 AR 031335A1 AR P010105299 A ARP010105299 A AR P010105299A AR P010105299 A ARP010105299 A AR P010105299A AR 031335 A1 AR031335 A1 AR 031335A1
Authority
AR
Argentina
Prior art keywords
combinations
inhibitors
recaptation
serotonine
new uses
Prior art date
Application number
ARP010105299A
Other languages
English (en)
Inventor
Bartoszyk Gerd Dr
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of AR031335A1 publication Critical patent/AR031335A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso de compuestos que son combinaciones de inhibidores selectivos de la recaptacion de serotonina (5HT) (SSRI) y agonistas del receptor 5-HT1A, en particular 1-[4-(5-cianoindol-3-il)butil]-4-(2-carbamoíl-benzofuran-5-il)-piperazina o una sal aceptable para uso fisiologico de la misma o 3-{4-[4-(4-ciano-fenil)-piperazin-1-il]-butil}-1H-indol-5- carbonitrilo o una sal aceptable para uso fisiologico del mismo, en la elaboracion de un medicamento destinado a la medicina veterinaria para el tratamiento o la profilaxis de trastornos traumáticos autodirigidos asociados con estresores del comportamiento y trastornos compulsivos asociados con estresores del comportamiento.
ARP010105299A 2000-11-14 2001-11-14 Nuevos usos de combinaciones de agonistas de 5-ht1a e inhibidores de la recaptacion de serotonina AR031335A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00124815 2000-11-14

Publications (1)

Publication Number Publication Date
AR031335A1 true AR031335A1 (es) 2003-09-17

Family

ID=8170369

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105299A AR031335A1 (es) 2000-11-14 2001-11-14 Nuevos usos de combinaciones de agonistas de 5-ht1a e inhibidores de la recaptacion de serotonina

Country Status (22)

Country Link
US (1) US20040082594A1 (es)
EP (1) EP1333832B1 (es)
JP (1) JP2004513924A (es)
KR (1) KR20030059244A (es)
CN (1) CN1222291C (es)
AR (1) AR031335A1 (es)
AU (2) AU2002215027B2 (es)
BR (1) BR0115296A (es)
CA (1) CA2428511C (es)
CZ (1) CZ302484B6 (es)
DE (1) DE60131675T2 (es)
ES (1) ES2296820T3 (es)
HK (1) HK1060697A1 (es)
HU (1) HUP0302751A3 (es)
MX (1) MXPA03004166A (es)
NO (1) NO20032148D0 (es)
PL (1) PL204331B1 (es)
RU (1) RU2288719C2 (es)
SK (1) SK287337B6 (es)
UA (1) UA79583C2 (es)
WO (1) WO2002040024A1 (es)
ZA (1) ZA200304606B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10305739A1 (de) 2003-02-11 2004-08-19 Merck Patent Gmbh Benzofuranderivate
DE602004014190D1 (de) 2003-12-23 2008-07-10 Lundbeck As Valby H 2-(1h-indolylsulfanyl)-benzylaminderivate als ssri
US7893261B2 (en) 2004-03-26 2011-02-22 Baylor University Serotonin reuptake inhibitors
AR052308A1 (es) 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
WO2006034788A1 (en) * 2004-09-28 2006-04-06 Merck Patent Gmbh Combinations of n-(indolecarbonyl-)piperazine derivatives and serotonin reuptake inhibitors
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
RU2462462C2 (ru) * 2006-08-11 2012-09-27 ДСМ АйПи АССЕТС Б.В. Производные лигустилида для лечения расстройств центральной нервной системы

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4333254A1 (de) * 1993-09-30 1995-04-06 Merck Patent Gmbh Piperidine und Piperazine
DE19512639A1 (de) * 1995-04-05 1996-10-10 Merck Patent Gmbh Benzonitrile und -fluoride
DE19637237A1 (de) * 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate
DE19730989A1 (de) * 1997-07-18 1999-01-21 Merck Patent Gmbh Piperazin-Derivate
SK492001A3 (en) * 1998-07-20 2001-08-06 Merck Patent Gmbh Biphenyl derivatives

Also Published As

Publication number Publication date
AU2002215027B2 (en) 2006-10-05
PL360310A1 (en) 2004-09-06
CN1222291C (zh) 2005-10-12
HUP0302751A3 (en) 2007-06-28
CN1474691A (zh) 2004-02-11
SK6382003A3 (en) 2003-11-04
RU2288719C2 (ru) 2006-12-10
DE60131675D1 (de) 2008-01-10
EP1333832A1 (en) 2003-08-13
NO20032148L (no) 2003-05-13
SK287337B6 (sk) 2010-07-07
MXPA03004166A (es) 2003-09-22
KR20030059244A (ko) 2003-07-07
JP2004513924A (ja) 2004-05-13
CZ302484B6 (cs) 2011-06-08
US20040082594A1 (en) 2004-04-29
UA79583C2 (en) 2007-07-10
ES2296820T3 (es) 2008-05-01
NO20032148D0 (no) 2003-05-13
ZA200304606B (en) 2004-09-13
CA2428511A1 (en) 2002-05-23
CZ20031433A3 (cs) 2003-09-17
HK1060697A1 (en) 2004-08-20
BR0115296A (pt) 2003-09-02
AU1502702A (en) 2002-05-27
DE60131675T2 (de) 2008-11-20
WO2002040024A1 (en) 2002-05-23
EP1333832B1 (en) 2007-11-28
HUP0302751A2 (hu) 2003-11-28
PL204331B1 (pl) 2010-01-29
CA2428511C (en) 2009-12-29

Similar Documents

Publication Publication Date Title
AR097388A1 (es) Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva
BR112016008016A2 (pt) inibidores de kras g12c
AR109816A2 (es) Forma de dosificación farmacéutica para administración oral de un inhibidor de la familia bcl-2
NO20052591L (no) Pyridopyrolizin og pyridoindolizinderivater
HRP20050826B1 (hr) Ciklički inhibitori proteinske tirozin kinaze
MX2017003215A (es) Terapia de combinacion con cenicriviroc para el tratamiento de la fibrosis.
UY27870A1 (es) Nuevos derivados de quinuclidina-amida
DE602006012725D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
CO2021006482A2 (es) Ureas cíclicas
AR037629A1 (es) Formulaciones farmaceuticas que comprenden un derivado de platino
UA90460C2 (ru) Фармацевтический препарат, который включает антитело против рецептора egf
NO20056132L (no) Krystallinsk form av beta2 adrenergisk receptoragonist
AR031335A1 (es) Nuevos usos de combinaciones de agonistas de 5-ht1a e inhibidores de la recaptacion de serotonina
AR033179A1 (es) Combinacion de farmacos para inhalacion
DK1703905T3 (da) Indol-derivater og anvendelse deraf som kinaseinhibitorer, især IKK2-inhibitorer
ES2530392T3 (es) Uso del nintedanib para el tratamiento de la fibrosis pulmonar
CA2971874A1 (en) Inhibition of trk kinase mediated tumor growth and disease progression
DE602006015509D1 (de) Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung
HRP20050322A2 (en) Use of dihydroimidazolones for the treatment of epilepsy in dogs
PE20010157A1 (es) Composiciones farmaceuticas que contienen inhibidores de oxido nitrico sintasa, inhibidores selectivos de la recaptacion de la serotonina, antagonistas del receptor nk-1
WO2006023187A3 (en) Cycloalkylamine derivatives as nk-1 /ssri antagonists
AR031463A1 (es) Uso de combinaciones de agonistas de 5-ht1a e inhibidores selectivos de la recaptacion de serotonina
RU2003115431A (ru) Новые применения объединенных агонистов 5-нт1а и ингибиторов обратного захвата серотонина
AR027394A1 (es) Uso de mirtazapina para el tratamiento de trastornos del sueno
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables

Legal Events

Date Code Title Description
FB Suspension of granting procedure